Forecasting The Future: 4 Analyst Projections For Gritstone Bio
Portfolio Pulse from Benzinga Insights
Over the past three months, four analysts have shared their evaluations of Gritstone Bio (NASDAQ:GRTS), revealing a mix of bullish and somewhat bullish sentiments. The average 12-month price target has decreased by 22.73% to $4.25. Analysts have adjusted their ratings and price targets, reflecting evolving market conditions and company performance. Gritstone Bio faces financial challenges, including a significant revenue decline, negative net margin, and high debt-to-equity ratio.
June 14, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Gritstone Bio has received mixed analyst ratings over the past three months, with a decrease in the average 12-month price target by 22.73% to $4.25. The company faces significant financial challenges, including a -90.96% revenue decline, negative net margin, and a high debt-to-equity ratio.
The mixed analyst ratings and significant decrease in the average price target indicate a bearish outlook. The company's financial challenges, including a substantial revenue decline and high debt-to-equity ratio, further support a negative short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100